Lenis

What Lenis does

Lenis farmacevtika d.o.o. is a Slovenia-headquartered, full-service specialty pharmaceutical commercialization and distribution partner serving the Central and Eastern Europe (CEE) and Adriatic regions. Founded in 2008 with a mission to cover unmet medical needs through unlicensed-medicine importation and Early Access Programs, Lenis now supplies more than 300 niche and specialty Rx medicines across infectious diseases, oncology, neurology, and nephrology through an integrated service stack that spans market analysis, regulatory affairs, market access, KOL engagement, local packaging adaptation, marketing and sales, pharmacovigilance, and wholesale distribution under GMP/GDP licenses.

The group's distribution footprint combines direct field-force presence in eight countries (Slovenia, Croatia, Bosnia and Herzegovina, Serbia, North Macedonia, Kosovo, Montenegro, and Albania) covering approximately 25 million people, with project-based distribution partnerships extending into Hungary, Czech Republic, Slovakia, Romania, Bulgaria, Poland, the Baltic states, the Nordics, Cyprus, and Malta — a total reach across more than 20 countries. Logistics are anchored by a regional warehouse partnership with Kemofarmacija (a member of the Phoenix Group) in Ljubljana and a bonded warehouse in Serbia for non-EU territory distribution. Two complementary assets sit alongside the core distribution business: the Quiba web application for antimicrobial prescribing guidance (integrated into Slovenian hospital information systems since 2023 through partnership with SRC Infonet) and a founding/lead-investor stake in Niba Labs d.o.o., which delivers digital PCR analytical services to gene therapy developers and partners with QIAGEN.

Lenis earns revenue primarily on a transaction-fee basis as a wholesale distributor and full-service commercialization partner for international pharmaceutical principals, complemented by service-fee work in regulatory affairs, market access, and pharmacovigilance. The customer base is enterprise B2B — chiefly international pharmaceutical suppliers (60+ principals pass annual compliance review) with end-customer reach into hospitals, pharmacies, and NGOs. The most strategic customer relationship is an exclusive full-service distribution mandate with Gilead Sciences for the Adriatic region held since 2010 and retained through a December 2025 majority investment by Great Point Partners (a Greenwich-based healthcare PE firm managing approximately $1.7B), which brought in former Biogen CEO Michel Vounatsos as Board Chairman and Richard Jones as CEO. Through the 2020 acquisition and 2022 legal merger of Medicopharmacia, Lenis consolidated 30+ years of Adriatic distribution experience into a single operating entity.

Name

Lenis

Legal name

Lenis farmacevtika d.o.o.

Website

https://lenis.si

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

Lenis is a Slovenia-based full-service specialty pharmaceutical distributor serving international pharmaceutical principals across the CEE and Adriatic regions, providing turnkey commercialization (regulatory, market access, distribution, pharmacovigilance) under GMP/GDP licenses in 8 direct and 20+ partner countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Ljubljana

HQ country

Slovenia

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical Distribution Services: Lenis generates revenue as a full-service specialty pharmaceutical distributor providing turnkey solutions for distribution needs across CEE markets. They supply registered innovative and generic medicines, manage early access programs, import unlicensed medicines, and address drug shortages.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Lenis is a Slovenian-based full-service pharmaceutical commercialization and distribution partner for international pharmaceutical principals seeking to access the CEE and Adriatic markets. Under GMP and GDP licenses, the company provides turnkey solutions including wholesale distribution, regulatory affairs, market access, medical support, pharmacovigilance, KOL mapping, local packaging adaptation, marketing & sales, market analysis, and public affairs for niche and specialty Rx medicines.

Product overview

Lenis is a Slovenian-based full-service specialty pharmaceutical commercialization and distribution partner serving the Central and Eastern Europe (CEE) and Adriatic regions. The company operates as a unified portfolio of integrated services rather than a single product: the core offering includes wholesale and distribution under GMP/GDP licenses, regulatory affairs, market access, medical support, pharmacovigilance, KOL mapping, local packaging adaptation, marketing and sales, market analysis, and public affairs. Supporting this core platform, Lenis offers two distinct digital/health technology tools: Quiba (a web application for antimicrobial prescribing guidance integrated into hospital information systems) and Niba Labs (a subsidiary providing therapeutic virus characterization services for gene therapy developers). Through its Medicopharmacia subsidiary, Lenis extends coverage across 8 countries of the Adriatic region with 25 million population, while maintaining a network of distribution partners across the broader CEE region from Baltic states to Malta. The company specializes in both registered innovative and generic medicines as well as unlicensed medicines and Early Access Programs.

Differentiator

Problem solved

Functional benefit

Brands

• Quiba: Digital application for appropriate prescribing of antimicrobial medicines developed with infectology experts
• Niba Labs

Products and services

• Wholesale & Distribution
• Regulatory Affairs
• Market Access
• Medical Support
• Pharmacovigilance
• KOL Mapping & Engagement
• Local Packaging Adaptation
• Marketing & Sales
• Market Analysis
• Public Affairs
• Quiba
• Niba Labs Digital PCR Services

Quantifiable outcome

• Successfully managed 60+ different medicine suppliers with annual compliance reviews passed
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature1 record

Partnerships

Four partnerships are on record, tiered core and minor.

• Evive BiotechcoreChannel Partner/ Reseller/ Distributor · 6 June 2025Lenis Group signed an exclusive distribution agreement with Evive Biotech to commercialize Ryzneuta in 8 markets in Central and Eastern Europe.
• Gilead SciencescoreChannel Partner/ Reseller/ DistributorLenis has been the exclusive full-service distributor for Gilead Sciences in the Adriatic region since 2010. The partnership was maintained after the Great Point Partners investment in 2025.
• KemofarmacijacoreChannel Partner/ Reseller/ DistributorSlovenia's largest wholesaler and member of the Phoenix Group, serving as Lenis's third-party logistics provider managing the regional warehouse in Ljubljana.
• Niba LabsminorStrategic or Co-development PartnerLenis is the founding member and lead investor in Niba Labs d.o.o., a spinout company developing technologies for characterization and quantification of therapeutic viruses used in gene therapy.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Others

• Hemofarm: Serbian pharmaceutical manufacturer and distributor (STADA group) with strong Balkan footprint. Comparable CEE/Adriatic orientation and specialty focus, but operates from the manufacturing side rather than as Lenis's distributor-led model.
• STADA Arzneimittel AG: Germany-headquartered generics and specialty pharma group with deep CEE manufacturing and distribution presence (including Hemofarm in Serbia). Adjacent comparison as another CEE-focused pharma commercialization player, but Lenis is a distributor while STADA is a manufacturer.
• Medochemie: Cyprus-headquartered multinational pharmaceutical manufacturer with strong CEE distribution. Operates in one of Lenis's partner geographies and overlaps on specialty Rx categories, but is a manufacturer rather than a distribution services company.
• KRKA: Slovenian-headquartered generic pharmaceutical manufacturer with strong CEE and Adriatic sales networks. Same home market and overlapping regional customer base as Lenis, but KRKA is a manufacturer rather than a third-party distributor.

Regional players

• Sopharma Trading: Bulgarian pharmaceutical wholesaler and distributor serving the local market and adjacent Balkans. Directly comparable distribution role to Lenis but operating in a different geography within CEE.
• Oriola Corporation: Nordic pharmaceutical distributor and health products retailer covering Finland and the Baltics. Comparable in providing distribution + dose-dispensing + healthtech-adjacent services, but operates in a different geography than Lenis's Adriatic/CEE focus.

Broad incumbents

• Cencora (formerly AmerisourceBergen): Global pharmaceutical distributor and services provider including specialty distribution, commercialization, and consulting for biopharma principals. Comparable in offering pharma principals integrated distribution + market access, but at vastly larger scale.
• Alliance Healthcare: Wholesale division of Walgreens Boots Alliance operating across Europe; a comparable full-service pharma distribution and commercialization platform but with significantly broader geographic scope and scale than Lenis.
• Phoenix Group AG: Pan-European pharmaceutical wholesaler; Lenis uses its subsidiary Kemofarmacija for Slovenia logistics. Closest comparable in scale and CEE footprint but operating as a much larger incumbent across multiple Western and Central European markets.
• McKesson Europe: European arm of global pharmaceutical distributor McKesson, providing wholesale and specialty pharma services to manufacturers, pharmacies, and hospitals across Europe. Directly comparable services but significantly larger footprint and broader portfolio than Lenis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInsi.linkedin.com/company/lenis

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lenis